Share Price.com
Market Update Economic Events Directors Deals Commodities Prices News Market Movers

Redx Pharma records promising pre-clinical data for potential fibrosis treatment

Tuesday, 12th February 2019
Redx Pharma said it had recorded promising pre-clinical efficacy data for a lead fibrosis treatment compound.

New data was produced from three independent pre-clinical animal models of lung, kidney and liver fibrosis, all testing the company lead ROCK2 compound.

The data showed it was able to suppress collagen deposition and pathways associated with fibrosis, indicating that selective ROCK2 inhibition could have an impact on established fibrosis.

The data would be presented in more detail later in 2019 at a scientific meeting.

Redx said it planned to nomiate a drug candidate for the ROCK2 programme by mid 2019, following final safety evaluations.

If nominated for development, it would be developed as an orally-administered treatment, with first-in-man studies commencing in 2020.


At 9:22am: (LON:REDX) Redx Pharma Plc share price was +1.25p at 8p



Story provided by StockMarketWire.com

Related Shares: Redx Pharma

Share Search
Share Search Share Search

Visit the Share Search.
Share Search

Share News
Share News



SharePrice.com will do their best to ensure the quality of the information displayed on this site, but all information is provided as-is, free of charge. We cannot be held responsible for any loss, material or otherwise, due to incorrect information found here. UK data supplied by NBTrader and Digital Look. Share Prices are at least 15 minutes delayed.